Full Press Release Details
Media
• February 27, 2025
IRWD Positive Sentiment
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance
Key Takeaway: Ironwood Pharmaceuticals has announced its financial results for the fourth quarter and full year of 2024. The company successfully met its financial guidance for the year, indicating strong performance. This achievement reflects positively on Ironwood's operational strategies and market position.
Price reaction · baseline $1.71 (2025-02-26 close) · hit after-hours · clean, no other IRWD news in the window
day 0 close
-5.3%
day 1
-5.8%
day 3 · peak
-12.9%
Market Sentiment Analysis
POSITIVE FACTORS
- Ironwood Pharmaceuticals achieved its 2024 financial guidance.
- The report indicates strong performance in the fourth quarter.
- Positive outlook for future growth and stability.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+57%
120-day peak, hindsight
Typical move
3.8%
average across 2 past catalysts
Lead asset
IW-3718
Phase 3 · Gastroesophageal Reflux Disease (GERD)
Frequently Asked Questions
What financial results did Ironwood report?
Ironwood Pharmaceuticals reported its fourth quarter and full year 2024 results.
Did Ironwood meet its financial guidance for 2024?
Yes, Ironwood achieved its financial guidance for the year 2024.